Here's the announcement from two weeks ago, Zygel is patent protected for autism while our BTX's have Permetrex in their patent applications for a variety of skin conditions and are well ahead in their development as Zygel' s Phase2 trial results are not expected till the second half of 2020.
https://zynerba.com/zynerba-pharmaceuticals-initiates-phase-2-trial-of-zygel-in-autism-spectrum-disorder/
https://zynerba.com/zynerba-pharmaceuticals-receives-new-u-s-patent-for-treatment-of-fragile-x-syndrome-with-cannabidiol/
